scholarly journals Malignant Peritoneal Mesothelioma Without Asbestos Exposure

2019 ◽  
Vol 12 (1) ◽  
pp. 48-51 ◽  
Author(s):  
Hafsa Abbas ◽  
Julio C Rodriguez ◽  
Hassan Tariq ◽  
Masooma Niazi ◽  
Ahmed Alemam ◽  
...  
Keyword(s):  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma

scholarly journals Synchronous multiple primary malignant neoplasms: a case report of malignant peritoneal mesothelioma and neuroendocrine rectal tumor

2021 ◽  
pp. 81-86
Author(s):  
Oleksandr Bondar ◽  
Sergiі Chetverikov ◽  
Viacheslav Maksymovskyi ◽  
Dmytro Atanasov ◽  
Mykhailo Chetverikov ◽  
...  
Keyword(s):  
Minimally Invasive ◽  
Argon Plasma Coagulation ◽  
Asbestos Exposure ◽  
Rectal Tumor ◽  
Peritoneal Mesothelioma ◽  
Special Treatment ◽  
Malignant Neoplasms ◽  
Malignant Peritoneal Mesothelioma ◽  
Invasive Treatment ◽  
Abdominal Tumor

We report a rare case of synchronous malignant peritoneal mesothelioma of the biphasic histological type and neuroendocrine tumor (NET) of the rectum without history of asbestos exposure. During 2 years since manifestation of the disease the patient underwent 3 cytoreductive surgeries (CRS): removal of the tumor of the sigmoid mesentery, resection of the rectosigmoid junction completeness of cytoreduction (CC) 0 (2017), omentectomy and partial parietal peritonectomy CC-0 (2017), atypical resection of S2, S4, S5 liver, the removal of the abdominal tumor with left-sided en-block hemicolectomy, partial parietal peritonectomy, argon-plasma coagulation of tumor foci on the mesentery of the small intestine CC-2 (2018) and Transanal Minimally Invasive Surgery-removal of neuroendocrine rectal tumor (2017). The patient underwent hyperthermic intraperitoneal chemotherapy (HIPEC) twice (during 2nd and 3rd CRS). Different regimens of HIPEC were performed: cisplatin + doxorubicin (2017) and metamycin C (2018). The patient received 4 courses of adjuvant chemotherapy with cisplatin plus pemetrexed in 2017 and 3 courses of the chemotherapy with gemcitabine and carboplatin plus bevacizumab in 2018. The patient survived 21 months after the detection of malignant peritoneal mesothelioma in 2017 and died 4 months after the last cytoreductive surgery from the progression of the disease. Histological subtype of MPMP remains important factor in the prognosis of the disease even on the early stages though patient had received the most aggressive variant of special treatment. Minimally invasive treatment tactics of NET demonstrated clinical effectiveness.  

A single-center retrospective cohort study evaluating the role of neoadjuvant chemotherapy in malignant peritoneal mesothelioma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21093-e21093
Author(s):  
Xiao Wang ◽  
Sharyn I. Katz ◽  
Leonid Roshkovan ◽  
Suzanne Walker ◽  
Sally McNulty ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cohort Study ◽  
Systemic Therapy ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Asbestos Exposure ◽  
Symptom Relief ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Single Center

e21093 Background: Malignant peritoneal mesothelioma (MPM) is a rare variant of malignant mesothelioma, representing < 30% of cases. Standard of care is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) when feasible. The benefit of systemic chemotherapy (chemo) (Neoadjuvant- N, Adjuvant- A, or 1st-line metastatic –M) is not well established and some retrospective studies report worse outcomes with N chemo. However, our institution has favored use of N chemo prior to surgery for symptom relief and surgical optimization. We conducted a single-center retrospective cohort study of MPM patients treated at our institution to evaluate the effect of N vs. A chemo on outcomes. Methods: We identified non-papillary MPM patients via ICD9/10 codes seen at our institution between 1/1/2009 and 9/1/2019. Pts were followed until 1/1/2020. Patients without pathologic diagnosis were excluded. We explored the effect of receipt of CRS, type of systemic therapy, and histology on overall survival. Median overall survival (mOS) from diagnosis was estimated from Kaplan-Meier curves. A Cox proportional hazard model computed hazard ratios (HR) to assess the effect of the exposure on OS. Results: We identified 47 patients with non-papillary MPM: median age 62 years, 77% epithelioid histology, 74.5% white, 55.3% known asbestos exposure. CRS was performed in 24 (51%) and 18/24 (75%) received HIPEC. The majority received systemic therapy (34/47 (72%)). Among those that received chemo and surgery, N chemo was more common than A chemo (N:12 (all platinum/pemetrexed), A:7). Median OS was 52.7 months (mo) overall and 77.2 mo with surgery vs 20.2 mo without (log rank p = 0.006). Toxicity from N chemo did not prevent surgery with 8/12 successfully receiving surgery (1 surgery scheduled, 2 lost to follow up). Of the 10 pts with evaluable scans: 5 had radiographic reduction of disease (2 complete responses by RECIST 1.1), 4 stable disease and 1 with disease growth. N chemo reduced ascites in 3 out of 4 pts with baseline ascites. N chemo was not associated with worse mOS compared to A chemo (HR 0.64, 95% CI 0.1-3.0, p = 0.62). Non-epithelioid histology was not associated with a worse OS compared to epithelioid (HR 1.5, 95% CI 0.6-4.1, p = 0.4). Conclusions: N chemo was not associated with worse outcomes compared to A chemo and toxicity from N chemo did not preclude surgery. In addition, N chemo resulted in reduction of disease burden and ascites in pts with MPM.

Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features

2013 ◽  
Vol 17 (1) ◽  
pp. 99-103 ◽  
Author(s):  
Yuichi Kinoshita ◽  
Kosho Takasu ◽  
Takashi Yuri ◽  
Katsuhiko Yoshizawa ◽  
Norihisa Uehara ◽  
...  
Keyword(s):  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma

scholarly journals MALIGNANT PERITONEAL MESOTHELIOMA -AN UNFORGOTTEN ABDOMINAL MALIGNANCY

2019 ◽  
pp. 1-2
Author(s):  
A. Mishra ◽  
Ashish Luthra ◽  
C. R. Behera ◽  
Ranjita Panigrahi ◽  
Ranjan Sahoo
Keyword(s):  
Unusual Case ◽  
Asbestos Exposure ◽  
Abdominal Cavity ◽  
Immunohistochemical Analysis ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Tumor Spread ◽  
Tunica Vaginalis Testis ◽  
Abdominal Malignancy ◽  
Rare Malignancy

Malignant peritoneal mesothelioma is a rare lethal malignancy of the serosal membranes of the peritoneum. The pathogenesis and association is strongly related with industrial pollutants asbestos, but less than pleural mesothelioma. Symptoms are nonspecific and related to the tumor spread within the abdominal cavity. CT scan is the investigation of choice and mostly disease is discovered incidentally on routine imaging. Diagnosis is confirmed on histopathology as well as immunohistochemical analysis of markers. The mainstay of treatment is cytoreductive surgery with Hyperthermic intraperitoneal chemotherapy. Here we present a very unusual case of malignant peritoneal mesothelioma diagnosed on routine evaluation of a 62 year old male admitted in emergency for obstructed inguinal hernia. Introduction: Malignant peritoneal Mesothelioma MPM is a very rare malignancy of the abdominal cavity. Mesotheliomas usually originate from the serosal membrane of different body cavities. Pleura is most commonly affected by mesothelioma followed by peritoneum and also other cavities pericardium and tunica vaginalis testis.10 to 30% of all mesothelioma affects peritoneum. Malignant peritoneal mesothelioma is a highly lethal malignant tumor of peritoneum and its pathogenesis is strongly related with industrial pollutant asbestos exposure. Diagnosis is difficult in most of the cases because of its nonspecific presentation and detected on routine abdominal imaging or Surgery

scholarly journals Sarcomatoid malignant peritoneal mesothelioma presenting as a localized mesenteric tumor with no previous asbestos exposure

2020 ◽  
Vol 2020 (10) ◽  
Author(s):  
Yves Alain Notue ◽  
Ulrich Igor Mbessoh ◽  
Grace Nganwa ◽  
Judith Ngo Pambe ◽  
Alain Chichom Mefire ◽  
...  
Keyword(s):  
Clinical Presentation ◽  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Mesenteric Tumor

Abstract Sarcomatoid malignant peritoneal mesothelioma is the rarest and most lethal form of peritoneal mesothelioma. We present the case of a sarcomatoid malignant peritoneal mesothelioma presenting as a localized mesenteric tumor in a 54-year-old female with no previous asbestos exposure. This clinical presentation is extremely rare and is the first documented in Cameroon.

scholarly journals Localized Biphasic Malignant Peritoneal Mesothelioma with Rhabdoid Features Involving the Liver: Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Dalal Hassan ◽  
Saverio Ligato
Keyword(s):  
Abdominal Wall ◽  
Surgical Resection ◽  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Microscopic Appearance ◽  
Lateral Abdominal Wall ◽  
Rare Tumors ◽  
History Of ◽  
Rhabdoid Features

Introduction. Localized malignant mesotheliomas, defined as sharply circumscribed tumors of the serosal membrane with the microscopic appearance of diffuse malignant mesothelioma, are rare tumors; their behavior and prognosis are uncertain. Intrahepatic mesotheliomas are postulated to arise from mesothelial cells of Glisson’s capsule. Case Presentation. A 69-year-old female with no history of asbestos exposure presented with a one-month history of increasing abdominal pain associated with constitutional symptoms. Computerized Tomography (CT) scan of the abdomen and pelvis revealed a sizable soft tissue mass within the right paracolic gutter, abutting the inferior hepatic margin, the lateral abdominal wall, and descending colon. Ultrasound-guided biopsy of the mass suggested a poorly differentiated hepatocellular carcinoma. There was no disease elsewhere on PET scan. Surgical resection of the mass was performed. Pathological assessment suggested the tumor to be arising from the liver with invasion of the liver, abdominal wall musculature, and the adventitial surface of the ascending colon. A final diagnosis of localized biphasic malignant peritoneal mesothelioma with rhabdoid features was rendered based on morphology and the result of immunohistochemical studies. The abdominal wall margin was positive. The patient progressed over the course of 6 months despite receiving adjuvant chemotherapy and immunotherapy with metastases and a decline in performance status and was transitioned to hospice. Conclusion. Localized malignant peritoneal mesotheliomas are rare tumors that may present clinically as a liver mass and simulate primary hepatic or secondary tumors. Definitive diagnosis is obtained by surgical resection in most cases. The clinical outcome is variable with most cases having a poor outcome.

scholarly journals Malignant peritoneal mesothelioma without asbestos exposure: An ovarian cancer imitator

2015 ◽  
Vol 11 ◽  
pp. 10-12 ◽  
Author(s):  
Kassondra S. Grzankowski ◽  
Rachel M. Brightwell ◽  
John M. Kasznica ◽  
Kunle O. Odusi
Keyword(s):  
Ovarian Cancer ◽  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma

Malignant Peritoneal Mesothelioma

2005 ◽  
Vol 91 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Vincenzo de Pangher Manzini
Keyword(s):  
Survival Time ◽  
Peritoneal Fluid ◽  
Clinical Presentation ◽  
Asbestos Exposure ◽  
Response To Therapy ◽  
Peritoneal Mesothelioma ◽  
X Rays ◽  
Malignant Peritoneal Mesothelioma ◽  
Difficult Diagnosis ◽  
Fluid Cytology

Background The clinical characteristics of malignant peritoneal mesothelioma are not fully known, and it appears as a variable entity with different types of clinical presentation and with a difficult diagnosis. Patients Fifteen patients with malignant peritoneal mesothelioma were analyzed for asbestos exposure, clinical presentation, thrombocytosis, X-rays and echotomographic findings, peritoneal fluid cytology, surgical investigations, diagnosis in vita, therapy, cause of death, diagnosis time, and survival time. Results Asbestos exposure was present in 12 men. Abdominal pain, ascites, abdominal mass, weight loss and fever were the most common presentation symptoms. In 5 patients, the disease presented as a surgical emergency. Assembling the presenting symptoms, malignant peritoneal mesothelioma was subdivided in 3 types: classical (6 cases), surgical (5 cases) and medical (4 cases). Thrombocytosis was present in 11 cases. Peritoneal fluid cytology was positive for neoplastic mesothelial cells in 8 of 10 cases. Laparotomy (5 patients) and laparoscopy (7 cases) were diagnostic in all cases. Diagnosis in vita was malignant peritoneal mesothelioma for 13 patients, peritoneal carcinomatosis for 1, with only 1 autopsy diagnosis. Seven patients were treated with chemotherapy, showing a progression of the disease. Mean symptoms-to-diagnosis time was 122 days (4-410), and mean symptoms-to-survival time was 345 days (45-1510). Conclusions Malignant peritoneal mesothelioma is a very unusual disease characterized by a difficult diagnosis, a rapid evolution, a poor response to therapy, and a very high prevalence of thrombocytosis. A new clinical classification into three types (classical, surgical and medical) may be useful for a correct diagnosis. The early diagnosis of malignant peritoneal mesothelioma remains an important open question.

Sign in / Sign up

Export Citation Format

Share Document